甲磺酸伊马替尼用于慢性粒细胞白血病临床治疗的效果分析

摘要

目的 研究并探讨甲磺酸伊马替尼用于慢性粒细胞白血病临床治疗中的效果.方法 选择2013年1月至2017年1月嘉兴市第二医院血液科收治的慢性粒细胞白血病患者60例纳入研究,采取计算机随机数字表法将60例患者分为对照组、观察组各30例.对照组、观察组分别实施常规化疗、常规化疗+甲磺酸伊马替尼口服.治疗6个月后,比较两组临床疗效、不良反应发生率、免疫功能指标、生存质量评分.结果 观察组客观缓解率为76.67％(23/30),对照组为50.00％(15/30),观察组高于对照组(χ2=4.593,P<0.05);观察组不良反应发生率为13.33％(4/30),明显低于对照组的36.67％(11/30)(χ2=4.356,P<0.05);治疗前,两组各项免疫功能指标差异均无统计学意义(t=0.168、0.287、0.156,均P>0.05),治疗后,观察组各项免疫功能指标均高于对照组(t=4.482、3.731、3.361,均P<0.05);治疗后,观察组各项生存质量评分均高于对照组(t=8.898、5.945、9.309、5.679,均P<0.05).结论 在慢性粒细胞白血病患者中采用甲磺酸伊马替尼治疗,可有效提高患者的近期疗效和化疗安全性,还可有效减轻化疗对患者免疫功能的影响,改善其生存质量.%Objective To study and explore the clinical effect of imatinib mesylate in the treatment of chronic myeloid leukemia. Methods From January 2013 to January 2017,60 patients with chronic myeloid leukemia in the Second Hospital of Jiaxing were included in the study. The patients were randomly divided into control group and observation group,with 30 cases in each group. The control group was given routine chemotherapy, the observation group was given routine chemotherapy combined wth imatinib mesylate orally. After 6 months of treatment,the clinical curative effect, the incidence of adverse reactions, immune function, quality of life score of the two groups were compared. Results The response rate of the observation group was 76. 67％ (23/30),which was higher than 50. 00％(15/30) of the control group (χ2 =4. 593,P <0. 05). The incidence rate of adverse reactions in the observation group was 13. 33％(4/30),which was significantly lower than 36. 67％(11/30) in the control group (χ2 =4. 356,P<0. 05). Before treatment,the immune function indicators between the two groups had no statistically significant differences (t=0. 168,0. 287,0. 156,all P>0. 05). After treatment,the indicators of immune function in the observation group were higher than those in the control group(t =4. 482,3. 731,3. 361,all P <0. 05). After treatment,the quality of life scores in the observation group were higher than those in the control group( t=8. 898, 5. 945,9. 309,5. 679,all P<0. 05). Conclusion Imatinib mesylate in the treatment of patients with chronic myelog-enous leukemia can effectively improve the efficacy and safety of chemotherapy,reduce the effect of chemotherapy on the immune function of patients,improve their quality of life.